By Anna Rose Welch, Chief Editor, Biosimilar Development
The future sustainability of the biosimilar market will depend on several key factors, one of which is a reduction in the cost of goods (COGs). Without continued innovation in the manufacturing and analytical components of biosimilar development, the biosimilar value proposition becomes less feasible for pharma manufacturers.
For years, the need for a low-cost manufacturing approach to antibodies has been top of mind for Ard Tijsterman, CEO of virtual biotech BiosanaPharma. This has been especially true in the face of what he sees as a “genericized” biosimilar industry with steep pricing discounts.